Browse Studies — Arctuva

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

Background: People with neurofibromatosis 1 (NF1) who have plexiform neurofibromas (pNFs) can have pain that affects their daily lives. This study aims to imp…

Neurofibromatosis 1Plexiform Neurofibromas

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT02544022

DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins

The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibro…

NeurofibromasMPNST

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT07298083

Phase 1

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

This study is designed to establish the foundation for a new therapy for neurofibromatosis Type I (NF1)-related cutaneous neurofibromas (cNFs) by assessing the…

NF1NeurofibromatosisCutaneous Neurofibroma+3 more

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07102394

Phase 1

A Phase 1/1b Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PAS-004, a MAPK/ERK Kinase 1/2 (MEK 1/2) Inhibitor, in Adult Participants With Neurofibromatosis Type 1 (NF1) With Symptomatic and Inoperable, Incompletely Resected, or Recurrent Plexiform Neurofibromas

The main purpose of this clinical trial is to test PAS-004 in people with at least one symptomatic plexiform neurofibroma due to Neurofibromatosis Type 1 (NF1)…

NF1 MutationNeurofibroma PlexiformNeurofibroma, Plexiform+2 more

Estimated

~$10 – $8,750

Pasithea Therapeutics Corp.NCT06961565